Notably, selumetinib in combination with osimertinib did not improve upon the osimertinib/phenformin combination in this model despite the osimertinib/selumetinib combination being very effective in a transgenic model of EGFR-driven lung cancer [24]. The gene discussed is EGFR; the disease is lung cancer.